Business Wire

Lightbits Grows Revenues By Over 5X in 2020 While Driving Innovation Through Technology Advancements and Patents

Share

Lightbits Labs, the pioneer and leader in NVMe™ over TCP (NVMe/TCP) software-defined storage, increased sales by more than 500 percent through a significant uptick in infrastructure as a service (IaaS), software as a service (SaaS), financial services, and video gaming customers.

Sales growth was fueled in part by the company’s strong partnerships, to which Intel was added in late September and also included new funding from Intel Capital. The partnership is designed to propel development of disaggregated storage solutions to solve the challenges of today’s data center operators who are craving improved storage efficiency and capacity utilization while maintaining compatibility with existing infrastructure without compromising performance and simplicity. This strategic partnership includes technical co-engineering, go-to-market collaboration, as well as the financial investment.

“In so many ways and for so many people 2020 was a very difficult year. Lightbits is fortunate that we were able to keep our employees safe through remote work, while also achieving and exceeding our goals for the year – including growing our customer base, enhancing our products, and expanding our partnerships and investors,” said Eran Kerzner, CEO. “We fully anticipate a strong surge in our sales throughout 2021.”

Last year, Lightbits announced significant product advancements, introducing LightOS™ 2.0 in June enabling full cloud-native persistent storage with high availability. The technological innovation solidified the company's position as a leader in scalable and efficient cloud-native storage that’s easy to consume for customers' private, hybrid, and edge cloud deployments. In December, the company released LightOS™ 2.1 that further enhances high-performance, scalability, and low latency so Lightbits’ customers can unleash hyperscale storage, but at a fraction of the cost of even the most advanced cloud storage offerings. As an example, Lightbits’ LightOS outperforms even the latest Amazon EBS io2 Block Express volumes with 5 times lower latency (200µs), 6 times the IOPS per volume (1.5M), twice the throughput per volume (8GB/s), 4 times larger volume size (256TB), and has features such as resizable volumes and multi-attach that are still roadmap items for io2 Block Express.

Through these advancements, Lightbits expanded the use cases for its patented solutions, including NVMe as a Service, as part of the IaaS umbrella. For financial services, use cases expanded to include database acceleration and Monte Carlo simulation. And under the SaaS umbrella, Lightbits LightOS gained traction as a high-performance replacement for Ceph.

In addition, Lightbits applied for five new patents that were accepted by the U.S. Patent Office, bringing the number of patents held by Lightbits to 20. The newly minted patents improve key functions within the NVMe/TCP storage architecture and help Lightbits protect its innovative approach to improving storage capacity utilization, reducing latency, and improving garbage collection features.

“With its blend of performance and high availability based around industry standards, NVMe/TCP offers a compelling value proposition for those needing extremely high performance in the composable block storage market,” said Eric Burgener, Research Vice President, Infrastructure Systems, Platforms and Technologies Group at IDC Research. “Lightbits Labs has significantly contributed to the NVMe/TCP standard and is continuing to improve upon the standard with its latest IP.”

Details on the new and existing Lightbits Labs patents can be found in the links below:

Among the milestones, 2020 drove several notable industry recognitions including:

Additional Resources:

About Lightbits Labs™

Lightbits Labs’ mission is to lead the cloud-native data center transformation by delivering scalable and efficient software defined storage that is easy to consume. Founded in 2016, Lightbits brings the agility of hyperscale storage to private clouds and edge clouds. The company pioneered NVMe/TCP so the solution is easy to deploy at scale, while delivering performance that is similar to local flash. Lightbits Labs is backed by strategic investors including Cisco Investments, Dell Technologies Capital, Intel Capital, and Micron, as well as top investors and VCs including Avigdor Willenz, Lip-Bu Tan, Marius Nacht, SquarePeg Capital, and WRVI Capital.

Visit www.lightbitslabs.com or contact us at info@lightbitslabs.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Alan Ryan
pr@lightbitslabs.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye